Fig. 7. ERG-positive tumor cells are particularly sensitive to SPOP inhibition.

a SPOP inhibitor (SPOP-i, compound 6b) mediated 3D growth inhibition in methylcellulose in the indicated prostate cancer cell lines. b Tumor growth kinetics with (n = 10) or without (vehicle; n = 10) SPOP-i treatment in xenografts established from LuCaP-147 (SPOP-Y83C) PDX cells. c Tumor growth kinetics with (n = 4) or without (vehicle; n = 4) SPOP-i treatment in xenografts established from LuCaP-78 (SPOP-W131G) PDX cells. d Tumor growth kinetics with (n = 11) or without (vehicle; n = 11) SPOP-i treatment in xenografts established from VCaP. e Tumor growth kinetics with (n = 6) or without (vehicle; n = 8) SPOP-i treatment in LuCaP-23.1 (ERG-positive) f Tumor growth kinetics with (n = 8) or without (vehicle; n = 10) SPOP-i treatment in LuCaP-35 (ERG-positive) PDX PDX. All SPOP-i treatment initiated when tumors reached an average of 100 mm³. g Dose–response curves to SPOP-i treatment of Mouse Prostate Organoids overexpressing ΔERG, SPOP-Y87C and Control vector. All error bars, mean + s.e.m. P-values were determined by two-way ANOVA with multiple comparisons and adjusted using Šidák post-test. NS, not significant. ****P < 0.0001. Molecular weights are indicated in kilodaltons (kDa). Source data are provided as a Source Data File.